Hand in Hand Progress | Zhuowei Technology and Xinyi Biotechnology Sign Strategic Cooperation Agreement

On December 15th, Jiangsu Zhuowei Biotechnology Co., Ltd. (hereinafter referred to as "Zhuowei Technology") and Beijing Xinyi Biotechnology Co., Ltd. (hereinafter referred to as "Xinyi Biotechnology") signed a strategic cooperation agreement at the Weijing International Hotel in the Global Dinosaur City. The two parties exchanged and reached cooperation in technology research and development, product development, market promotion, and other aspects.

Zhuowei Technology and Xinyi Biotechnology are both leaders in their respective technical fields. They complement each other's advantages in the field of digital PCR molecular detection with Zhuowei Technology's rapid and accurate particle detection, and form a strong alliance with Xinyi Biotechnology. With their strong technological platforms, they work together to create complete solutions in multiple fields such as medical diagnosis and food inspection. At the same time, both sides will strengthen complementary channel construction, jointly explore the market, promote the continuous output of innovative products by enterprises in the region, and deeply practice the concept of a community with a shared future for mankind and a community of human health and hygiene.

About Xinyi Biology

Xinyi Biotechnology was founded in 2015 and is located in Zhongguancun Science Park. It is a national high-tech enterprise and a "specialized, refined, and innovative" enterprise in Beijing. It focuses on independent innovation of molecular diagnostic technology and the application and transformation of major diseases. It has a high-level R&D team in the fields of instruments, chips, materials, reagents, software, and more. The company has developed rapidly, applying for more than 190 domestic and foreign patents, granting more than 100 patents, continuously publishing academic papers in authoritative journals, and undertaking national research funds. The digital PCR system developed by the company based on independent intellectual property rights won the registration certificate of the first COVID-19 detection reagent NMPA Class III medical device based on digital PCR technology, won the gold medal of excellent innovative products in vitro diagnostics in China for two consecutive years, and won the general champion of Zhongguancun International Frontier Science and Technology Innovation Competition. The company adheres to the concept of "innovation, making precision within reach", develops multi index, high-throughput, automation, pollution prevention, and low-cost molecular diagnostic technology, and is committed to becoming a leading life science and molecular diagnostic enterprise, serving life science, precision medicine, drug development, and health management.

About Zhuowei Technology

Zhuowei Technology was founded in March 2014, with a long-term focus on the development of instruments for cytology and particle detection on microfluidic chips. Through years of accumulation in microfluidic chip technology, we have mastered the processes of polymer material fixed chips that can achieve tens of thousands of detections and consumable chips with a minimum detection accuracy of 0.5 microns. Adhering to Kurt's characteristic technical principles, combined with imaging methods, flow cytometry, cytology automation and other technologies, modular combinations are formed to form multiple microfluidic cytology products.